Investors Praise Bristol Myers Squibb for Boosting Access to Life-Saving AIDS Drugs Via Medicines Patent Pool
Author: Interfaith Center on Corporate Responsibility (USA), Published on: 12 December 2013
Licensing agreement reached for generic production of...Atazanavir shows leadership and innovation in delivering HIV/AIDS medicines where they are most needed. Members of the Interfaith Center on Corporate Responsibility (ICCR) today applaud Bristol-Myers Squibb (BMS) for...[its] agreement with the Medicines Patent Pool (MPP) for its drug Atazanavir (ATV). ICCR members...have been encouraging global pharmaceutical companies to share their patents...to increase their accessibility...for the world’s most vulnerable populations... The new agreement will allow for...manufacture...by generics manufacturers...and its sale in 110 countries which is expected to cover 88.4% of people living with HIV in middle- and low-income countries...“We view the addition of BMS...as a possible tipping point for the pharmaceutical sector,” said Pat Zerega of Mercy Investment Services...Said Julie Tanner of Christian Brothers Investment Services, “In addition...ICCR members praise AbbVie for entering into formal negotiations with the MPP for pediatrics..."